Adaptimmune Therapeutics PLC — Director's Dealing 2021

Jul 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2021-07-01

Reporting Person: Behbahani Ali (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-01	Option to purchase Ordinary Shares	$0.71	A	474385	Acquired	2031-07-01	Ordinary Shares (474385)	Direct

Footnotes

F1: The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount.